

Koji Tamada

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3879065/publications.pdf>

Version: 2024-02-01

48
papers

11,502
citations

236925
25
h-index

276875
41
g-index

48
all docs

48
docs citations

48
times ranked

14429
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. <i>Nature Medicine</i> , 2002, 8, 793-800.	30.7	4,217
2	B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. <i>Nature Medicine</i> , 1999, 5, 1365-1369.	30.7	2,200
3	B7-H3: A costimulatory molecule for T cell activation and IFN- γ production. <i>Nature Immunology</i> , 2001, 2, 269-274.	14.5	856
4	Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. <i>Cancer Research</i> , 2005, 65, 1089-96.	0.9	687
5	IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. <i>Nature Biotechnology</i> , 2018, 36, 346-351.	17.5	496
6	LIGHT, a TNF-Like Molecule, Costimulates T Cell Proliferation and Is Required for Dendritic Cell-Mediated Allogeneic T Cell Response. <i>Journal of Immunology</i> , 2000, 164, 4105-4110.	0.8	355
7	B7-H1 Determines Accumulation and Deletion of Intrahepatic CD8+ T Lymphocytes. <i>Immunity</i> , 2004, 20, 327-336.	14.3	352
8	Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. <i>Nature Medicine</i> , 2000, 6, 283-289.	30.7	293
9	B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. <i>Blood</i> , 2010, 116, 1291-1298.	1.4	287
10	Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies. <i>Clinical Cancer Research</i> , 2012, 18, 6436-6445.	7.0	217
11	Cutting Edge: Expression of Functional CD137 Receptor by Dendritic Cells. <i>Journal of Immunology</i> , 2002, 168, 4262-4267.	0.8	216
12	B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function. <i>Blood</i> , 2001, 97, 1809-1816.	1.4	201
13	Restoring Immune Function of Tumor-Specific CD4+ T Cells during Recurrence of Melanoma. <i>Journal of Immunology</i> , 2013, 190, 4899-4909.	0.8	173
14	Signaling Through NK Cell-Associated CD137 Promotes Both Helper Function for CD8+ Cytolytic T Cells and Responsiveness to IL-2 But Not Cytolytic Activity. <i>Journal of Immunology</i> , 2002, 169, 4230-4236.	0.8	162
15	Cutting Edge: Selective Impairment of CD8+ T Cell Function in Mice Lacking the TNF Superfamily Member LIGHT. <i>Journal of Immunology</i> , 2002, 168, 4832-4835.	0.8	88
16	Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. <i>Cancer Science</i> , 2015, 106, 945-950.	3.9	78
17	In vitro growth inhibition of a broad spectrum of tumor cell lines by activated human dendritic cells. <i>Blood</i> , 2000, 95, 2346-2351.	1.4	70
18	Selective targeting of the LIGHT-HVEM costimulatory system for the treatment of graft-versus-host disease. <i>Blood</i> , 2007, 109, 4097-4104.	1.4	66

#	ARTICLE	IF	CITATIONS
19	RELT, a new member of the tumor necrosis factor receptor superfamily, is selectively expressed in hematopoietic tissues and activates transcription factor NF- κ B. <i>Blood</i> , 2001, 97, 2702-2707.	1.4	59
20	Dichotomous regulation of GVHD through bidirectional functions of the BTLA-HVEM pathway. <i>Blood</i> , 2011, 117, 2506-2514.	1.4	49
21	Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 201-211.	4.2	46
22	Improved survival of chimeric antigen receptor α -engineered T (<scp>CAR</scp> α T) and tumor α -specific T cells caused by anti α -programmed cell death protein 1 single α -chain variable fragment α -producing <scp>CAR</scp> α T cells. <i>Cancer Science</i> , 2019, 110, 3079-3088.	3.9	36
23	Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy. <i>Annals of Gastroenterological Surgery</i> , 2018, 2, 289-303.	2.4	35
24	Blockade of LIGHT/LT β and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2002, 109, 549-557.	8.2	32
25	Combined adjuvants of poly(I:C) plus LAG α 3 α lg improve antitumor effects of tumor α -specific T cells, preventing their exhaustion. <i>Cancer Science</i> , 2016, 107, 398-406.	3.9	31
26	Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2503-2515.	4.2	28
27	Anti α -tumor efficacy of human anti α -c α -met CAR α T cells against papillary renal cell carcinoma in an orthotopic model. <i>Cancer Science</i> , 2021, 112, 1417-1428.	3.9	21
28	PD-L1 on mast cells suppresses effector CD8 $^{+}$ T-cell activation in the skin in murine contact hypersensitivity. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 563-573.e7.	2.9	19
29	High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer. <i>PLoS ONE</i> , 2020, 15, e0226707.	2.5	16
30	β 1-Acid Glycoprotein Enhances the Immunosuppressive and Protumor Functions of Tumor-Associated Macrophages. <i>Cancer Research</i> , 2021, 81, 4545-4559.	0.9	16
31	Pathogenic Function of Herpesvirus Entry Mediator in Experimental Autoimmune Uveitis by Induction of Th1- and Th17-Type T Cell Responses. <i>Journal of Immunology</i> , 2016, 196, 2947-2954.	0.8	15
32	Microbial biomarkers for immune checkpoint blockade therapy against cancer. <i>Journal of Gastroenterology</i> , 2018, 53, 999-1005.	5.1	15
33	Herpesvirus entry mediator regulates hypoxia-inducible factor α 1 α and erythropoiesis in mice. <i>Journal of Clinical Investigation</i> , 2011, 121, 4810-4819.	8.2	12
34	GM-CSF derived from the inflammatory microenvironment potentially enhanced PD-L1 expression on tumor-associated macrophages in human breast cancer. <i>Scientific Reports</i> , 2022, 12, .	3.3	11
35	Identification of a Promiscuous Epitope Peptide Derived From HSP70. <i>Journal of Immunotherapy</i> , 2019, 42, 244-250.	2.4	10
36	In vitro growth inhibition of a broad spectrum of tumor cell lines by activated human dendritic cells. <i>Blood</i> , 2000, 95, 2346-2351.	1.4	10

#	ARTICLE	IF	CITATIONS
37	A phase I study of multi-HLA-binding peptides derived from heat shock protein 70/glypican-3 and a novel combination adjuvant of hLAG-3Ig and Poly-ICLC for patients with metastatic gastrointestinal cancers: YNP01 trial. Cancer Immunology, Immunotherapy, 2020, 69, 1651-1662.	4.2	9
38	Enhanced Antitumor Responses of Tumor Antigen-Specific TCR T Cells Genetically Engineered to Produce IL7 and CCL19. Molecular Cancer Therapeutics, 2022, 21, 138-148.	4.1	9
39	Cancer Immunotherapy Targeting Co-signal Molecules. Advances in Experimental Medicine and Biology, 2019, 1189, 313-326.	1.6	4
40	Novel bone microenvironment model of castration-resistant prostate cancer with chitosan fiber matrix and osteoblasts. Oncology Letters, 2021, 22, 689.	1.8	3
41	Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. , 0, .		1
42	Induction of antigen specific CD8+ T cell infiltration by a novel neoadjuvant vaccine containing HSP70 and GPC3 peptides plus soluble LAG-3 and Poly-IC:LC: Interim results of a Phase I study.. Journal of Clinical Oncology, 2019, 37, e14306-e14306.	1.6	1
43	A phase I study of novel multi-HLA-binding peptides and a new combination of immune adjuvants against solid tumors.. Journal of Clinical Oncology, 2017, 35, 3086-3086.	1.6	0
44	A phase I study of multi-HLA-binding HSP70 + GPC3 peptides and combination adjuvants of LAG3-Ig + Poly-ICLC against gastrointestinal cancers.. Journal of Clinical Oncology, 2018, 36, e15167-e15167.	1.6	0
45	Title is missing!., 2020, 15, e0226707.		0
46	Title is missing!., 2020, 15, e0226707.		0
47	Title is missing!., 2020, 15, e0226707.		0
48	Title is missing!., 2020, 15, e0226707.		0